SPC Financial Inc. Takes $1.01 Million Position in Hologic, Inc. (NASDAQ:HOLX)

SPC Financial Inc. acquired a new stake in Hologic, Inc. (NASDAQ:HOLX) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 12,892 shares of the medical equipment provider’s stock, valued at approximately $1,005,000.

Other institutional investors have also added to or reduced their stakes in the company. McGlone Suttner Wealth Management Inc. purchased a new stake in Hologic during the 4th quarter valued at $27,000. Massmutual Trust Co. FSB ADV boosted its position in Hologic by 69.4% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock valued at $40,000 after buying an additional 227 shares during the period. Allworth Financial LP boosted its position in Hologic by 39.3% during the 4th quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 179 shares during the period. Mather Group LLC. purchased a new stake in Hologic during the 1st quarter valued at $48,000. Finally, Toth Financial Advisory Corp boosted its position in Hologic by 81.1% during the 1st quarter. Toth Financial Advisory Corp now owns 775 shares of the medical equipment provider’s stock valued at $60,000 after buying an additional 347 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Needham & Company LLC restated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a report on Friday, May 3rd. Evercore ISI decreased their price objective on shares of Hologic from $78.00 to $76.00 and set an “in-line” rating for the company in a report on Tuesday, July 2nd. Stephens assumed coverage on shares of Hologic in a report on Thursday, June 27th. They issued an “overweight” rating and a $87.00 price objective for the company. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Finally, Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $80.00 to $95.00 in a report on Wednesday, April 3rd. Five research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Hologic has an average rating of “Moderate Buy” and a consensus target price of $85.55.

Hologic Stock Performance

Shares of NASDAQ HOLX traded up $0.72 during trading on Thursday, reaching $76.49. 1,440,377 shares of the company traded hands, compared to its average volume of 1,619,373. The company has a quick ratio of 3.29, a current ratio of 3.97 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $17.85 billion, a PE ratio of 38.97, a P/E/G ratio of 2.48 and a beta of 0.99. The firm has a 50 day simple moving average of $73.99 and a 200-day simple moving average of $74.48. Hologic, Inc. has a 52-week low of $64.02 and a 52-week high of $82.45.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.05. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The firm’s revenue was down .8% compared to the same quarter last year. During the same quarter last year, the firm posted $1.06 earnings per share. Equities research analysts anticipate that Hologic, Inc. will post 4.08 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.